{
    "clinical_study": {
        "@rank": "10090", 
        "arm_group": [
            {
                "arm_group_label": "Group A (lapatinib ditosylate, surgery)", 
                "arm_group_type": "Experimental", 
                "description": "Patients receive lapatinib ditosylate PO BID on days -2 to 0. Within 3-5 hours after last dose of lapatinib ditosylate, patients undergo surgery on day 0."
            }, 
            {
                "arm_group_label": "Reference Group (surgery)", 
                "arm_group_type": "Active Comparator", 
                "description": "Patients undergo surgery on day 0."
            }
        ], 
        "brief_summary": {
            "textblock": "This pilot clinical trial studies lapatinib tosylate before surgery in treating patients\n      with recurrent high-grade glioma. Lapatinib tosylate may stop the growth of tumor cells by\n      blocking some of the enzymes needed for cell growth."
        }, 
        "brief_title": "Lapatinib Tosylate Before Surgery in Treating Patients With Recurrent High-Grade Glioma", 
        "condition": [
            "Adult Anaplastic Astrocytoma", 
            "Adult Anaplastic Ependymoma", 
            "Adult Anaplastic Oligodendroglioma", 
            "Adult Giant Cell Glioblastoma", 
            "Adult Glioblastoma", 
            "Adult Gliosarcoma", 
            "Adult Mixed Glioma", 
            "Recurrent Adult Brain Tumor"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Astrocytoma", 
                "Brain Neoplasms", 
                "Ependymoma", 
                "Glioblastoma", 
                "Glioma", 
                "Oligodendroglioma", 
                "Gliosarcoma"
            ]
        }, 
        "detailed_description": {
            "textblock": "PRIMARY OBJECTIVES:\n\n      I. To achieve an intratumoral lapatinib (lapatinib ditosylate) concentration of at least 1.5\n      \u00b5M in at least 70% of patients 3 hours after the last dose of pulsatile lapatinib. (Group A)\n      II. To determine the pharmacodynamic (PD) effect of pulsatile lapatinib (at pulsatile\n      maximum tolerated dose [MTD]) on epidermal growth factor receptor (EGFR) phosphorylation\n      (using Mesoscale Discovery enzyme-linked immunosorbent assay [ELISA] assay for total and\n      phospho-EGFR). (Group A and Reference Group)\n\n      SECONDARY OBJECTIVES:\n\n      I. To evaluate the safety profile of pulsatile lapatinib in pre-operative patients with EGFR\n      amplified recurrent high-grade glioma. (Group A and Reference Group) II. To determine the\n      effect of lapatinib on tumor cell proliferation (marker of proliferation Ki-67 [KI-67]\n      staining) (Group A compared to Reference Group).\n\n      III. To determine the ex-vivo sensitivity of tumor sphere cultures to lapatinib. (Group A\n      and Reference Group)\n\n      OUTLINE: Patients are assigned to 1 of 2 treatment groups.\n\n      GROUP A: Patients receive lapatinib ditosylate orally (PO) twice daily (BID) on days -2 to\n      0. Within 3-5 hours after last dose of lapatinib ditosylate, patients undergo surgery on day\n      0.\n\n      REFERENCE GROUP: Patients undergo surgery on day 0.\n\n      After completion of study treatment, patients are followed up for at least 30 days."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Patients must have histologically proven World Health Organization (WHO) grade IV\n             glioblastoma/ gliosarcoma or WHO grade III glioma (anaplastic astrocytoma, anaplastic\n             oligodendroglioma, mixed anaplastic oligoastrocytoma, anaplastic ependymoma) which is\n             progressive or recurrent following radiation therapy +/- chemotherapy\n\n          -  Patients must have measurable, supratentorial contrast-enhancing progressive or\n             recurrent high-grade glioma by magnetic resonance imaging (MRI) imaging within 21\n             days of starting treatment; patient must be able to tolerate MRIs\n\n          -  Patients may have an unlimited number of prior therapy regimens\n\n          -  Patients must have recovered from severe toxicity of prior therapy; the following\n             intervals from previous treatments are required to be eligible:\n\n               -  12 weeks from the completion of radiation\n\n               -  6 weeks from a nitrosourea chemotherapy\n\n               -  3 weeks from a non-nitrosourea chemotherapy\n\n               -  4 weeks from any investigational (not Food and Drug Administration\n                  [FDA]-approved) agents\n\n               -  2 weeks from administration of a non-cytotoxic, FDA-approved agent (e.g.,\n                  hydroxychloroquine, etc.)\n\n          -  Patients must be undergoing surgery that is clinically indicated as determined by\n             their care providers; patients must be eligible for surgical resection according to\n             the following criteria: expectation that the surgeon is able to resect at least 500\n             mg of tumor from enhancing tumor and 100 mg from non-enhancing tumor with low risk of\n             inducing neurological injury\n\n          -  Patient tumor sample must have evidence of EGFR gene amplification by chromogenic in\n             situ  hybridization (CISH) performed at central site\n\n          -  Paraffin embedded tissue must be available from initial surgical resection at\n             diagnosis (prior to any treatment)\n\n          -  Patients must have a Karnofsky performance status >= 60% (i.e. the patient must be\n             able to care for himself/herself with occasional help from others)\n\n          -  Absolute neutrophil count >= 1,500/mcL\n\n          -  Platelets >= 100,000/mcL\n\n          -  Hemoglobin >= 9 g/dL\n\n          -  Total bilirubin =< institutional upper limit of normal\n\n          -  Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase\n             [SGOT])/alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase [SGPT])\n             =< 3 \u00d7 institutional upper limit of normal\n\n          -  Creatinine =< institutional upper limit of normal OR creatinine clearance >= 60\n             ml/min/1.73 m^2 for patients with creatinine levels above institutional normal\n\n          -  Activated partial thromboplastin time (APTT)/partial thromboplastin time (PTT) =< 1.5\n             x institutional upper limit of normal\n\n          -  Group A patients: Left ventricular ejection fraction (LVEF) within normal\n             institutional limits\n\n          -  Patients must be able to provide written informed consent\n\n          -  Group A patients: Women of childbearing potential must have a negative serum\n             pregnancy test prior to study entry; women of childbearing potential and men must\n             agree to use adequate contraception (hormonal or barrier method of birth control;\n             abstinence) prior to study entry and for the duration of study participation; should\n             a woman become pregnant or suspect she is pregnant while participating in this study,\n             she should inform her treating physician immediately; men treated or enrolled on this\n             protocol must also agree to use adequate contraception prior to the study, for the\n             duration of study participation, and for 4 months after completion of lapatinib\n             administration\n\n          -  Patients must have no concurrent malignancy except curatively treated basal or\n             squamous cell carcinoma of the skin or carcinoma in situ of the cervix, breast, or\n             bladder; patients with prior malignancies must be disease-free for >= five years\n\n          -  Group A: Patients must be able to swallow medication by mouth, either tablets or\n             dispersed tablets in solution\n\n        Exclusion Criteria:\n\n          -  Patients may not be receiving any other investigational agents\n\n          -  Group A: Patients with a history of allergic reactions attributed to compounds of\n             similar chemical or biologic composition to lapatinib are ineligible; the lapatinib\n             Investigator Brochure can be referenced for more information\n\n          -  Patients with prior therapy with EGFR inhibitors are ineligible; patients with prior\n             EGFRvIII vaccine are eligible if recurrent tumor is positive for EGFR gene\n             amplification\n\n          -  Patients on enzyme-inducing anti-epileptic drugs (EIAED) are not eligible for\n             treatment on this protocol; patients may be on non-enzyme inducing anti-epileptic\n             drugs or not be taking any anti-epileptic drugs; patients previously treated with\n             EIAED may be enrolled if they have been off the EIAED for 10 days or more prior to\n             the first dose of lapatinib\n\n          -  Patients must not have evidence of significant hematologic, renal, or hepatic\n             dysfunction\n\n          -  Patients must not have evidence of significant intracranial hemorrhage\n\n          -  Patients with uncontrolled intercurrent illness including, but not limited to,\n             hypertension, ongoing or active infection, symptomatic congestive heart failure,\n             unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social\n             situations that would limit compliance with study requirements, are ineligible\n\n          -  Group A: Pregnant women are excluded from this study; breastfeeding should be\n             discontinued if the mother is treated with lapatinib\n\n          -  Group A: Human immunodeficiency virus (HIV)-positive patients on strong cytochrome\n             P450, family 3, subfamily A, polypeptide 4 (CYP3A4) inducers or inhibitors are\n             ineligible\n\n          -  Group A: Patients who have acute or currently active/requiring anti-viral therapy\n             hepatic or biliary disease are ineligible (with the exception of patients with\n             Gilbert's syndrome, asymptomatic gallstones, liver metastases from the primary brain\n             tumor, or stable chronic liver disease per investigator assessment)\n\n          -  Group A: Patients receiving P-glycoprotein (P-gp) inhibitors are ineligible"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "33", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "March 28, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02101905", 
            "org_study_id": "NCI-2014-00634", 
            "secondary_id": [
                "NCI-2014-00634", 
                "ABTC-1302", 
                "ABTC-1302", 
                "U01CA137443"
            ]
        }, 
        "intervention": [
            {
                "arm_group_label": "Group A (lapatinib ditosylate, surgery)", 
                "description": "Given PO", 
                "intervention_name": "lapatinib ditosylate", 
                "intervention_type": "Drug", 
                "other_name": [
                    "GSK572016", 
                    "GW-572016", 
                    "GW2016", 
                    "Lapatinib", 
                    "Tykerb"
                ]
            }, 
            {
                "arm_group_label": [
                    "Group A (lapatinib ditosylate, surgery)", 
                    "Reference Group (surgery)"
                ], 
                "description": "Undergo surgery", 
                "intervention_name": "therapeutic conventional surgery", 
                "intervention_type": "Procedure"
            }, 
            {
                "arm_group_label": [
                    "Group A (lapatinib ditosylate, surgery)", 
                    "Reference Group (surgery)"
                ], 
                "description": "Correlative studies", 
                "intervention_name": "pharmacological study", 
                "intervention_type": "Other", 
                "other_name": "pharmacological studies"
            }, 
            {
                "arm_group_label": [
                    "Group A (lapatinib ditosylate, surgery)", 
                    "Reference Group (surgery)"
                ], 
                "description": "Correlative studies", 
                "intervention_name": "laboratory biomarker analysis", 
                "intervention_type": "Other"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Lapatinib"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "lastchanged_date": "May 29, 2014", 
        "location": [
            {
                "contact": {
                    "email": "tcloughesy@mednet.ucla.edu", 
                    "last_name": "Timothy F. Cloughesy", 
                    "phone": "310-825-5321"
                }, 
                "facility": {
                    "address": {
                        "city": "Los Angeles", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "90095"
                    }, 
                    "name": "University of California at Los Angeles (UCLA )"
                }, 
                "investigator": {
                    "last_name": "Timothy F. Cloughesy", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "jhcccro@jhmi.edu", 
                    "last_name": "Stuart A. Grossman", 
                    "phone": "410-955-8804"
                }, 
                "facility": {
                    "address": {
                        "city": "Baltimore", 
                        "country": "United States", 
                        "state": "Maryland", 
                        "zip": "21287"
                    }, 
                    "name": "Johns Hopkins University/Sidney Kimmel Cancer Center"
                }, 
                "investigator": {
                    "last_name": "Stuart A. Grossman", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Tom Mikkelsen", 
                    "phone": "313-916-1784"
                }, 
                "facility": {
                    "address": {
                        "city": "Detroit", 
                        "country": "United States", 
                        "state": "Michigan", 
                        "zip": "48202"
                    }, 
                    "name": "Henry Ford Hospital"
                }, 
                "investigator": {
                    "last_name": "Tom Mikkelsen", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "mellingi@mskcc.org", 
                    "last_name": "Ingo K. Mellinghoff", 
                    "phone": "646-888-2766"
                }, 
                "facility": {
                    "address": {
                        "city": "New York", 
                        "country": "United States", 
                        "state": "New York", 
                        "zip": "10065"
                    }, 
                    "name": "Memorial Sloan-Kettering Cancer Center"
                }, 
                "investigator": {
                    "last_name": "Ingo K. Mellinghoff", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "Drug Distribution and Pharmacodynamic Study of Pulsatile Lapatinib in Surgically Accessible EGFR-Amplified Recurrent High-Grade Glioma", 
        "overall_official": {
            "affiliation": "National Cancer Institute (NCI)", 
            "last_name": "Timothy Cloughesy", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "January 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "measure": "Lapatinib ditosylate intratumoral concentration (pharmacokinetics)", 
                "safety_issue": "No", 
                "time_frame": "Baseline and day of surgery"
            }, 
            {
                "description": "A ratio of pEGFR/total EGFR at 80% reduction from a median value from the untreated reference group will be considered as the putative threshold to qualify a near complete inhibition of EGFR (at 80%).", 
                "measure": "Ratio of phosphorylated (p)EGFR/total EGFR (PD) in tumor tissue", 
                "safety_issue": "No", 
                "time_frame": "Day of surgery"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02101905"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "All treatment or surgically related AEs will be reported descriptively. A proportion of toxicity grade >=3 will be estimated using binomial distribution.", 
                "measure": "Incidence of adverse events (AEs)", 
                "safety_issue": "Yes", 
                "time_frame": "Up to day 30"
            }, 
            {
                "description": "Descriptive statistics will be used for summarizes results and Box plots could be used to present the difference between the treated and untreated groups.", 
                "measure": "Inhibition of tumor cell proliferation (KI-67)", 
                "safety_issue": "No", 
                "time_frame": "Day of surgery"
            }, 
            {
                "description": "The ex-vivo sensitivity of tumor sphere cultures established from surgical specimens to pulsatile lapatinib ditosylate is defined by a minimum of 20% reduction in cell proliferation as measured by cell titer glow in the pulsatile lapatinib ditosylate group compared to the untreated group. Fisher's exact test will be used for testing a difference in the proportion between the two groups.", 
                "measure": "Ex-vivo sensitivity of tumor sphere cultures to lapatinib ditosylate", 
                "safety_issue": "No", 
                "time_frame": "Day of surgery"
            }
        ], 
        "source": "National Cancer Institute (NCI)", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "National Cancer Institute (NCI)", 
                "agency_class": "NIH"
            }
        }, 
        "start_date": "March 2014", 
        "study_design": "Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}